Skip to content

Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease

Impact of Concurrent Low Intensity Shockwave Therapy on Clinical Outcomes With Collagenase Clostridium Histolyticum in Peyronie's Disease: A Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06065436
Enrollment
60
Registered
2023-10-04
Start date
2024-01-19
Completion date
2027-01-31
Last updated
2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction, Peyronie Disease

Brief summary

The purpose of this research is to determine whether or not low-intensity shockwave therapy (LiSWT) with Xiaflex treatment will result in greater improvements to the curvature of the penis.

Interventions

DRUGCollagenase Clostridium Histolyticum

Total of 8 Intralesional injection (0.90 mg), administered as four separate injection series. Within each series, subjects will receive two injections, administered approximately 1-7 days apart.

DEVICEStorz Duolith LiSWT

Single low intensity shockwave therapy consistent of 1,500 shocks at a rate of 120 shocks/minute and using a power setting of 0.09 mJ/mm2. These treatments will occur four separate times, before each of the four separate CCH injection series.

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• Diagnosed with PD * Palpable penile plaque * Dorsal, lateral, or dorsolateral penile curvature * Penile curvature \> 30 degrees and \< 90 degrees as measured using goniometer during objective curvature assessment * Non-calcified plaque or grade 1 calcification (stippling, no shadowing) as determined by penile duplex Doppler ultrasound (PDDU) * Stable PD symptoms' defined as PD symptom duration \> 6-months or stable symptoms \> 3-months

Exclusion criteria

* Prior intralesional injections or surgery for PD. * Severe baseline penile pain. * Moderate or severe baseline ED based on IIEF-EF domain. * History of low intensity shockwave therapy for sexual dysfunction (ED or PD). * Ventral (downward) or ventrolateral penile curvature. * Moderate or severe (grade 2/3) plaque calcification as determined by PDDU. * Inability to achieve satisfactory erection rigidity at time of baseline curvature assessment.

Design outcomes

Primary

MeasureTime frameDescription
Change in symptom botherBaseline, 6 weeksMeasured using the validated Peyronie's Disease Questionnaire (PDQ) subdomain symptom bother. Four questions to evaluate pain or discomfort during vaginal intercourse: responses include not at all bothered, a little bit bothered , moderately bothered, very bothered, extremely bothered
Change in penetrative sexual intercourseBaseline, 6 weeksMeasured using self-reported question: Over the past 4 weeks: When you attempted intercourse, how often were you able to penetrate (enter) your partner? Responses include no sexual activity, almost never or never , a few times (less than half the time), sometimes (about half the time), Most times (more than half the time), almost always or always.
Surgical straightening intervention6 weeksNumber of subjects to require surgical straightening
Change in erectile functionBaseline, 6 weeksMeasured using the International Index of erectile Function
Change in Erectile Function Domain (IIEF-EF)Baseline, 6 weeks

Countries

United States

Contacts

Primary ContactWyatt H Anians, CCRP
Anians.Wyatt@mayo.edu507-538-6151

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026